Application of combination of tetracycline medicine and fluconazole in preparation of antifungal product, and product thereof

A tetracycline drug and a combined application technology, applied in the field of medicine, can solve problems such as difficulty in clinical treatment of fungal infections, and achieve a strong effect.

Inactive Publication Date: 2012-08-08
QIANFOSHAN HOSPITAL OF SHANDONG
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The formation of BF is one of the important mechanisms of clinical drug resistance, and the clinical treatment of BF-associated fungal infections is very difficult

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of combination of tetracycline medicine and fluconazole in preparation of antifungal product, and product thereof
  • Application of combination of tetracycline medicine and fluconazole in preparation of antifungal product, and product thereof
  • Application of combination of tetracycline medicine and fluconazole in preparation of antifungal product, and product thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038] 1. Materials

[0039] 1.1 Drugs and reagents

[0040] Fluconazole (FLC), Shandong Chengchuang Pharmaceutical Technology Development Co., Ltd.;

[0041] Minocycline (minocycline, MINO), minocycline hydrochloride, Shandong Panxin Biotechnology Co., Ltd.;

[0042] Doxycycline (DOX), Shandong Drug Testing Institute;

[0043] CHROMagar Candida Chromogenic Medium, Zhengzhou Bosai Biological Engineering Co., Ltd.;

[0044] TTC-Sapauer agar, Hangzhou Tianhe Microbiological Reagent Co., Ltd.;

[0045] Sodium hydroxide, state-owned Shandong Shanxian Organic Chemical Factory, batch number 940420;

[0046] Potassium dihydrogen phosphate, Shanghai Xinbao Fine Chemical Factory, batch number 200602132.

[0047] Dimethyl sulfoxide (DMSO), China Yaoshun Import and Export Co., Ltd., batch number 031012;

[0048] RPMI 1640 API powder, American GIBCO company;

[0049] 3-(N-morpholino)propanesulfonic acid (MOPS), Jinan Pengyuan Biotechnology Co., Ltd.;

[0050] Menadione (Menadione)...

Embodiment 2

[0085] 1. Materials

[0086] 1.1. Drugs and reagents

[0087] Benidipine (benidipine hydrochloride, BEN), Huaxia Pharmaceutical Co., Ltd.;

[0088] EDTA, No.1 Reagent Factory, Shanghai, China;

[0089] Nifedipine (Nifedipine, NIF), Shandong Provincial Drug Testing Institute;

[0090] Doxycycline (DOX), National Institute of Drug Control;

[0091] Drug stock solution: all the following drug solutions are stored in a -20°C refrigerator for later use.

[0092] Benidipine was made into 2560μg / ml stock solution in DMSO

[0093] Minocycline was made into 6400μg / ml stock solution in DMSO

[0094] Fluconazole was made into 2560μg / ml stock solution with sterile distilled water

[0095] Doxycycline was made into 6400 μg / ml stock solution with sterile distilled water

[0096] Nifedipine was made into 6400 μg / ml stock solution with sterile distilled water

[0097] EDTA was made into 0.5M stock solution with sterile distilled water

[0098] Yeast extract-peptone-glucose (YPD) agar...

Embodiment 3

[0120] 1. Materials

[0121] 1.1 Drugs and reagents

[0122] Benidipine (benidipine hydrochloride, BEN), Huaxia Pharmaceutical Co., Ltd.;

[0123] EDTA, No.1 Reagent Factory, Shanghai, China;

[0124] Nifedipine (Nifedipine, NIF), a gift from the Pharmacology Laboratory of Huazhong University of Science and Technology;

[0125] Doxycycline (DOX), National Institute of Drug Control;

[0126] Drug stock solution: all the following drug solutions are stored in a -20°C refrigerator for later use.

[0127] Benidipine was made into 2560μg / ml stock solution in DMSO

[0128] Minocycline was made into 6400μg / ml stock solution in DMSO

[0129] Fluconazole was made into 2560μg / ml stock solution with sterile distilled water

[0130] Doxycycline was made into 6400 μg / ml stock solution with sterile distilled water

[0131] Nifedipine was made into 6400 μg / ml stock solution with sterile distilled water

[0132] EDTA was made into 0.5M stock solution with sterile distilled water

[0...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses an application of a combination of a tetracycline medicine and fluconazole (FLC) in the preparation of an antifungal product, and the product thereof, and concretely discloses a synergistic effect of three cell calcium regulators of a non-selective calcium channel retarding agent benidipine (BEN), a selective L-type calcium channel retarding agent nifedipine (NIF) and a calcium ion chelating agent ethylene diamine tetraacetic acid (EDTA) to the FLC and tetracycline antifungal medicines of doxycycline (DOX) and minocycline (MINO), and an application of the three cell calcium regulators in Candida albicans resisting, wherein a synergistic antifungal effect can be generated by the combined application of the FLC, the DOX and the MINO. Results confirm that the combined application of the FLC and the DOX / MINO can generate the synergistic antifungal effect, and has a substantial killing effect on drug-resistant Candida albicans; the BEN, the NIF and the EDTA can obviously enhance the combined antifungal effect of the FLC and the DOX / MINO to the Candida albicans, and can obviously reduce the lowest effective concentration during the combined application of the FLC, the MINO and the DOX; and the combined application of the three calcium regulators and the FLC can enhance the antifungal effect.

Description

technical field [0001] The invention relates to the field of medical technology, in particular to the application of tetracycline drugs doxycycline and minocycline combined with fluconazole in the preparation of antifungal products, and further relates to calcium channel blockers benidipine, nifedipine and calcium channel blockers Combined antifungal effects of ion chelator EDTA combined with fluclozole and fluconazole and doxycycline / minocycline against Candida albicans with different sensitivities. The present invention also relates to products containing the above components or contents. Background technique [0002] In recent years, with the increase in the incidence of malignant tumors, AIDS, and autoimmune diseases, the development of techniques such as catheter intubation and organ transplantation, and the widespread use of broad-spectrum antibiotics, corticosteroids, and immunosuppressants, the incidence of fungal infections has increased sharply. Rising (Odds FC. P...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/65A61K31/4196A61P31/10A61K31/4545A61K31/4422A61K31/198
Inventor 孙淑娟刘萍高媛
Owner QIANFOSHAN HOSPITAL OF SHANDONG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap